Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the detailed structural analysis and design of complex sugars (polysaccharides) for the development of improved versions of existing drugs, the development of novel drugs, and the discovery of new biological processes. We are also utilizing our ability to sequence, or analyze the molecular structure of, sugars to create technology-enabled generic versions of complex sugar-based products. Our most advanced product candidate, M-Enoxaparin, is designed to be a technology-enabled generic version of Lovenox®, a widely prescribed low molecular weight heparin, or LMWH. Our novel product candidates include M118, a LMWH for the treatment of acute coronary syndromes that has been designed to possess specific biological attributes as well as a technology that has been designed to use specific sugar sequences to improve the non-invasive delivery of drugs such as therapeutic proteins.